key: cord-0910063-ynwiynh9
authors: Mahroum, Naim; Watad, Abdulla; Bridgewood, Charlie; Mansour, Muhammad; Nasr, Ahmad; Hussein, Amr; Khamisy-Farah, Rola; Farah, Raymond; Gendelman, Omer; Lidar, Merav; Shoenfeld, Yehuda; Amital, Howard; Kong, Jude Dzevela; Wu, Jianhong; Bragazzi, Nicola Luigi; McGonagle, Dennis
title: Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic
date: 2021-08-30
journal: Int J Environ Res Public Health
DOI: 10.3390/ijerph18179149
sha: 943ec341fed77ded4e5d843fca5279fba0bf6a96
doc_id: 910063
cord_uid: ynwiynh9

Background. Tocilizumab is an anti-IL-6 therapy widely adopted in the management of the so-called “cytokine storm” related to SARS-CoV-2 virus infection, but its effectiveness, use in relation to concomitant corticosteroid therapy and safety were unproven despite widespread use in numerous studies, mostly open label at the start of the pandemic. Methods: We performed a systematic review and meta-analysis of case-control studies utilising tocilizumab in COVID-19 on different databases (PubMed/MEDLINE/Scopus) and preprint servers (medRxiv and SSRN) from inception until 20 July 2020 (PROSPERO CRD42020195690). Subgroup analyses and meta-regressions were performed. The impact of tocilizumab and concomitant corticosteroid therapy or tocilizumab alone versus standard of care (SOC) on the death rate, need for mechanical ventilation, ICU admission and bacterial infections were assessed. Results. Thirty-nine studies with 15,531 patients (3657 cases versus 11,874 controls) were identified. Unadjusted estimates (n = 28) failed to demonstrate a protective effect of tocilizumab on survival (OR 0.74 ([95%CI 0.55–1.01], p = 0.057), mechanical ventilation prevention (OR 2.21 [95%CI 0.53–9.23], p = 0.277) or prevention of ICU admission (OR 3.79 [95%CI 0.38–37.34], p = 0.254). Considering studies with adjusted, estimated, tocilizumab use was associated with mortality rate reduction (HR 0.50 ([95%CI 0.38–0.64], p < 0.001) and prevention of ICU admission (OR 0.16 ([95%CI 0.06–0.43], p < 0.001). Tocilizumab with concomitant steroid use versus SOC was protective with an OR of 0.49 ([95%CI 0.36–0.65], p < 0.05) as was tocilizumab alone versus SOC with an OR of 0.59 ([95%CI 0.34–1.00], p < 0.001). Risk of infection increased (2.36 [95%CI 1.001–5.54], p = 0.050; based on unadjusted estimates). Conclusion: Despite the heterogeneity of included studies and large number of preprint articles, our findings from the first eight of the pandemic in over 15,000 COVID-19 cases suggested an incremental efficacy of tocilizumab in severe COVID-19 that were confirmed by subsequent meta-analyses of large randomized trials of tocilizumab. This suggests that analysis of case-control studies and pre-print server data in the early stages of a pandemic appeared robust for supporting incremental benefits and lack of major therapeutic toxicity of tocilizumab for severe COVID-19.

"Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) has been identified as the infectious agent responsible for the potentially life-threatening "Coronavirus disease 2019" (COVID-19) [1] . Since December 2019, this virus has quickly spread out from China, becoming a global pandemic, with high death rates [1] [2] [3] .

In the absence of proven antiviral or vaccine strategies, with vaccines being approved only recently, there has been considerable interest in the dysregulated immune response accompanying SARS-CoV-2, since poor prognosis has been repeatedly shown to correlate with elevation of inflammatory markers [4] [5] [6] . Indeed, the analogy with a hypercytokinaemic state or cytokine storm that typically occurs in macrophage activation syndrome (MAS) has been made [7] . In the cytokine storm or MAS states, including those linked to chimeric antigen receptor T-cell therapy (CAR-T) or Still's disease, impressive responses have been reported with anti-cytokine therapy against interleukin 6 (IL-6) or interleukin 1 (IL-1) [8, 9] .

Tocilizumab is a monoclonal antibody targeting both the soluble and membranebound forms of the IL-6 receptor (IL-6R) [10] . By blocking IL-6R, tocilizumab prevents the cisand trans-activation of the JAK-STAT pathway as well as the MAPK/NFκB cascade and other networks triggered by IL-6, with consequent broad antagonism of both innate and adaptive immunity [10] . Tocilizumab is licensed for the treatment of rheumatoid arthritis (RA), systemic-onset polyarticular juvenile idiopathic arthritis (JIA), giant cell arteritis (GCA), and severe/life-threatening cytokine storm also known as cytokine release syndrome (CRS) secondary to the use of CAR-T cell therapy [11, 12] . Of note, subjects with severe COVID-19 pneumonia have been reported to have higher levels of detectable serum IL-6 levels [13] .

In the absence of definitive COVID-19 therapies in the face of a severe cytokine storm, tocilizumab has been proposed as a potential treatment, especially in individuals exhibiting high levels of inflammatory markers. Consequently, tocilizumab therapy has been at the vanguard of biological therapy for severe COVID-19 pneumonia with highly impressive initial reports from open-label studies from China [14] . However, some investigators have sounded a word of caution that the immune activation in COVID-19 is a lung specific immunopathology that may be reactive to an active ongoing viral pneumonitis and, unlike the CAR-T/Still's disease setting, the impact of tocilizumab, even though promising [15] , is far from clear. In addition, in Rheumatology practice, tocilizumab therapy is typically reserved for subjects that fail to adequately respond to disease-modifying antirheumatic drug (DMARDs) or require ongoing high dose chronic corticosteroid administration. However, chronic corticosteroid use is not needed for COVID-19 pneumonia and, in the face of an escalating pandemic and encouraging results from corticosteroid therapy, there is an urgent need to define the optimal use, if any, of tocilizumab in severe COVID-19 MAS pneumonia [16, 17] . Therefore, the purpose of the present systematic review and meta-analysis was to investigate whether tocilizumab therapy directed against severe COVID-19 improved survival. We investigated its effectiveness both in intensive care unit (ICU) and non-ICU settings, both in ventilated and not ventilated patients, and evaluated the impact of concomitant corticosteroid therapy on survival. With the sheer volume of rapidly appearing publications in this arena, we also stratified our analysis for an independent evaluation of peer reviewed and pre-print publications.

As tocilizumab use is associated with an increased risk of bacterial infections in the Rheumatology arena, we also evaluated its safety profile.

The study protocol was devised according to the "Preferred Reporting Items for Systematic reviews and Meta-Analyses-Protocol" (PRISMA-P) guidelines [18] . The findings are here reported according to the "Preferred Reporting Items for Systematic reviews and Meta-Analyses" (PRISMA) guidelines [19] . The systematic review and meta-analysis study protocol has been registered with PROSPERO Number CRD42020195690.

The following string of keywords was searched: "tocilizumab AND (2019-nCoV OR COVID-19 OR SARS-CoV-2)". Synonyms were used as well, such as "ACTEMRA", "IL-6 blocker" or "IL-6 blockade therapy" for tocilizumab and "novel coronavirus", "emerging coronavirus" or "Wuhan coronavirus", for the infectious agent. No time or language filters were applied. PubMed/MEDLINE and Scopus were extensively mined from inception until 20 July 2020, together with pre-print servers, namely medRxiv, Research Square and SSRN.

The following PICOS criteria were considered: Original investigations designed as case reports, case series and cross-sectional studies not providing information for each treatment cohort, as well as studies devised as editorials, letters to editor, commentaries, and reviews (of any type) were excluded.

Relevant data were independently extracted by two researchers (A.W. and N.L.B.): namely, reference, country in which the study was conducted, sample size (overall number of patients, those receiving tocilizumab plus standard care and those receiving standard care), inclusion and exclusion criteria, main demographic characteristics of the recruited sample, including age, sex, underlying co-morbidities, treatment received (tocilizumab dosage/schedule, starting of tocilizumab in relationship to time of admission, concomi-tant therapies such as antibiotics, antiviral medications including ritonavir/lopinavir or remdesivir, steroids and anticoagulants).

The following parameter(s)/outcome(s) were evaluated; clinical and laboratory parameters, admission to the ICU, need for mechanical ventilation, and side effects. Disagreements were resolved by discussion with the senior author (D.M.G.) until consensus was achieved.

Considering the emergency nature of the situation and given that tocilizumab has been administered in a compassionate, off-label way, and was not available in every healthcare facility, due to the general shortage of drugs, it was not always possible to perform a rigorous patient enrolment by applying stringent screening and inclusion/exclusion criteria. As such, most studies presented statistically significant differences between cases and controls, which calls up for caution when interpreting univariate, unadjusted results. To cope with these issues, we assessed whether the study authors adjusted for the outcomes, for example performing propensity-based inverse probability weighting models or multivariate analyses. Further details concerning research strategy are reported in Table 1 . Table 1 . Details of the search strategy adopted in the present systematic review and meta-analysis.

International scholarly electronic databases searched

PubMed/MEDLINE, Scopus, pre-print servers (medRxiv, SSRN, Research Square)

("SARS-CoV-2" OR "novel coronavirus" OR "emerging coronavirus" OR "Wuhan coronavirus" OR "2019-nCoV" OR "COVID-19") AND (tocilizumab OR Actemra OR "interleukin 6-blockade treatment"

OR "interleukin 6-blockade therapy" OR "IL-6-blockade treatment" OR "IL-6-blockade therapy" OR "IL-6 blocker") 

Quality assessment was performed independently by two researchers (A.W. and N.L.B.) by means of the Newcastle-Ottawa scale for case-control studies. This instrument comprises eight items investigating domains such as selection (four stars), comparability (two stars) and exposure (four stars). Specifically concerning comparability, one star was awarded in case of matching for socio-demographic parameters and a further star was given in case of homogenous pharmacological treatment between cases and controls.

Prevalence rates, odds-ratios (ORs) and hazard-ratios (HRs) were pooled together utilizing classical meta-analytical approaches. In more detail, when authors did not provide an already computed effect size, numbers of events for each outcome were extracted both for cases (patients receiving tocilizumab plus standard care) and controls (receiving standard care only) to compute the combined effect size together with its 95% confidence interval (CI). When authors provided an already computed effect size (generally adjusted), these were combined together. Based on the Q and I 2 tests, depending on the amount of heterogeneity among studies, a random-effects model was preferred over a fixed-effects one [20, 21] . For each outcome of interest, we present the overall combined effect size based on the 2 × 2 contingency table (unadjusted effect size), the combined effect size pooling together only those studies which performed case-control matching (adjusted effect size) and the various results at the single study level. In case of a significantly high amount of heterogeneity among studies, meta-regressions and sub-group analyses were performed to shed light on the determinants of such heterogeneity.

The presence of publication bias was assessed by visually inspecting the funnel plot and carrying out the Egger's linear regression test. All analyses were conducted with the commercial software "Comprehensive Meta-Analysis" (CMA version 3.0, for Windows, Biostat, Englewood, NJ, USA).

The initial search yielded a pool of 974 items with 39 studies included in the present systematic review and meta-analysis, totalling a sample of 15,531 patients (3657 cases versus 11,874 controls) . The process of retrieval, inclusion and exclusion process is pictorially shown in Figure 1 . The main characteristics of the studies retained are presented in Tables 2 and 3 . Of the 39 studies included, one [28] was exclusively devoted to the safety profile of tocilizumab, only 15 (38.5%) carried out propensity score-based inverse probability treatment weighting models or performed adjustments for mismatching between cases and controls by means of multivariate analyses. At the time of the search, 67% (n = 26) of the investigations retained were released as pre-prints. 

For 14 studies, no information was available regarding age. Mean age among cases ranged from 55 to 76.8 years. Of the included studies, slightly more than half (52.0%) were age mismatched between cases and controls, especially those with higher sample-sizes, a key consideration given that older age is linked to COVID-19 mortality. In 11 studies the cases and controls were aged matched and in three studies tocilizumab treated cases were older than controls (even though in one of these studies the difference did not achieve statistical significance), while in eleven studies the controls were older than tocilizumab treated cases. To see if age mismatching impacts on the outcomes of interest, meta-regressions and sub-group analyses were performed. Concerning gender distribution, overall, this did not differ between cases receiving tocilizumab and controls receiving standard care. In 10 studies, among cases there were less females than among controls. No other significant differences concerning other socio-demographic parameters could be found. A more detailed description of this data is found in Tables 2 and 3.

Overall, the rate of underlying co-morbidities was comparable between those treated with tocilizumab and controls in this 15,000-patient group study with only eight studies exhibiting differences between cases and controls (See Tables 2 and 3 ). These studies were generally small-medium size, with only one large-size.

Markers including CRP, D-dimer, CK, troponin-T and LDH level elevations are associated with poor prognosis in COVID-19 pneumonia and these collectively are thought to represent virally mediated immune-mediated thrombosis with hypoxemia with associated cardiac stress and increased mortality [7] . In the 39 studies, when reported, tocilizumab cases generally displayed worse prognostic biomarkers, such as higher IL-6 and CRP levels compared to controls. The overall oxygen saturation and PaO 2 /FiO 2 ratio were lower in the tocilizumab cases group pre-therapy than in controls. Collectively these poor prognostic features were over-represented in the tocilizumab treated groups (Tables 2 and 3 ).

Three studies did not provide information about standard care therapy; hydroxychloroquine was administered in 36 studies, antivirals and antiviral agents were provided in 27 studies and corticosteroids use was reported in 30 studies, without necessarily referring to posology or route of administration, thus complicating a detailed analysis of the impact of corticosteroids. Antibiotics were delivered in 36 studies, whereas anti-coagulants were administered in 12 studies. Generally, there was no difference in terms of drug use between the two groups. The three studies where tocilizumab was administered without steroids were otherwise balanced for the aforementioned alternative therapies. (Figure 2A) . At the meta-regressions level, no effects of study quality (selection p = 0.2629, comparability p = 0.2227, and exposure p = 0.2684) or publication status (pre-prints versus published in peer-reviewed journals; p = 0.4376) could be detected. No evidence of publication bias could be found ( Figure 2B ). Figure 2D ).

To study the impact of concomitant use of steroids, an exploratory meta-regression was conducted. Results of the meta-regression (p = 0.9450) indicated that tocilizumab administration was effective in both treatment cohorts, that is to say in those utilizing steroids and in those to whom corticosteroids were not administered. Tocilizumab with concomitant steroid use versus standard care, that may have also included steroid was protective with an OR 0.49 ([95%CI 0.36-0.65], p < 0.05), but it was not possible to accurately evaluate steroid use between the two groups. Tocilizumab alone (without steroid) versus standard care without steroid also appeared protective OR 0.59 ([95%CI 0.34-1.00], p < 0.001) in three studies ( Figure 2E ). 

Unadjusted estimates showed no protective effect (OR 3.79 [95%CI 0. 38-37.34] , p = 0.254) ( Figure 4A ). No effect of publication bias could be found ( Figure 4B ) as well as no effect of publication status (pre-print versus published in a peer-reviewed journal, p = 0.1627). However, two studies reported adjusted estimates of the impact of tocilizumab on reduction of ICU admission. Applying a fixed-effects model, pooling these two studies the combined effect size resulted in OR 0.16 ([95%CI 0.06-0.43], p < 0.001) ( Figure 4C ). 

A subgroup of COVID-19 patients develops severe pneumonia with some features of a cytokine storm, which may contribute to patient mortality [61, 62] . The emergent evidence of corticosteroid efficacy in severe COVID-19 disease in both open and controlled trials strongly attests to a pulmonary macrophage activation syndrome-like disease dramatically impacting on mortality [16, 17] . Interleukin-6 and several other cytokines are pivotal to the immunopathogenesis of cytokine storm, and IL-6 elevations have been reported in some severe COVID-19 studies [7, 63] . The COVID-19 pandemic is still escalating and treating physicians desperately need knowledge on the optimal use of corticosteroids and cytokine blockers, or both in combination for severe COVID-19 disease. This meta-analysis in over 15,000 COVID-19 using unadjusted estimates failed to show a reduction in mortality with tocilizumab, although a trend for reduced mortality was evident. An unadjusted analysis also failed to show a protective effect of tocilizumab on preventing mechanical ventilation and also ICU admission. According to adjusted models where patient numbers were much smaller, tocilizumab use was associated with an overall mortality reduction.

The data pertaining to the efficacy of tocilizumab or otherwise as an adjunct therapy added to corticosteroids were unclear at the start of the pandemic. In this metanalysis, accurate description of steroid dose between the tocilizumab and standard of care groups was not available which made data difficult to interpret.

During the first eight months of the pandemic, we became aware of a negative phase three randomised controlled trial of tocilizumab where we understand that corticosteroid was also part of the control group. The issue of the impact of corticosteroids needed further evaluation in the trial arena but had large health economic cost implications if the addition of tocilizumab to corticosteroid therapy improved survival. Indeed, we found some small trials that supported the efficacy of tocilizumab monotherapy where steroids were not part of the standard of care group [24, 25, 57] .

Despite the heterogeneity of included studies and large number of preprint articles, our findings from the first eight of the pandemic in over 15,000 COVID-19 cases suggested an incremental efficacy of tocilizumab in severe COVID-19 that were confirmed by subsequent meta-analyses of large randomized trials of tocilizumab [64] [65] [66] . This suggests that analysis of case-control studies and pre-print server data in the early stages of a pandemic appeared robust for supporting incremental benefits of tocilizumab for severe COVID-19.

In this meta-analysis, tocilizumab use was associated with an increased the risk of bacterial infection, but we could not link this to an increased mortality. Unlike the emergent data from the RECOVERY trial [16] where the beneficial impact of corticosteroid therapy was highest in ventilated cases, the available data in this meta-analysis precluded a specific analysis of the impact of tocilizumab therapy on mortality by patient stratification according to mechanical ventilation in ICU settings versus non-ICU.

Since the start of the COVID-19 pandemic, it has emerged that the immunopathogenesis of the accompanying cytokine storm may at least in part be due to unrestrained SARS-CoV2 replication due to blunting of both innate type-1 interferon responses and adaptive immune responses with severe lymphopenia and T-cell functional exhaustion. Indeed, use of high dose steroids in non-severe COVID-19 disease could potentially be detrimental to survival [16] . Consequently, IL-6R blocking might in some circumstances be counterproductive and could theoretically exacerbate severe disease.

Reassuringly, there was no evidence from our systematic review and meta-analysis of an increased mortality related to tocilizumab therapy, but optimal therapy especially in subjects with ongoing viral replication still needs to be defined. Furthermore, many ICU ventilated cases have acute respiratory distress syndrome (ARDS) which in severe cases may be linked to IL-6 elevations and given the role of IL-6 in tissue repair, the outcome of tocilizumab on ventilated ARDS cases is worthy of consideration. The toxicities of very high doses of steroids, including the induction of avascular necrosis in patients with severe hypoxaemia, and other steroid toxicities are avoided, which adds further reassuring data to the safety of cytokine antagonism.

Despite the inconclusiveness of some of the present data and the consistently high heterogeneity among studies included, information provided could be meaningful both for identifying an optimal patient/candidate for tocilizumab based treatment and for devising future treatment. Tissue repair will be a major issue in COVID-19 pneumonia. IL-6 can act on tissue remodelling and injury, and the timing and amount of antibodies to suppress injury can be an issue. In addition, IL-6 suppression does not resolve all of the aspects of the multifaceted pathophysiology of COVID-19 pneumonia, including cell death, abnormal coagulation and lung inflammation caused by viral infection.

The present systematic review and meta-analysis is not without shortcomings. The heterogeneity was high for all outcomes of interest, which represents a limitation of our study. However, this issue was addressed by means of meta-regressions and subgroup analyses to shed light on the determinants of such heterogeneity. Another major limitation is given by the inclusion of studies which, lacking of proper controls, do not perform adjustments for confounding factors, therefore masking the real potential effect of tocilizumab administration. Generally, the tocilizumab therapy group was younger than the control group, but this was balanced by a greater magnitude elevation in inflammatory makers and underlying co-morbidities. However, the effect of each co-variate, including age, gender, and co-morbidities, was assessed by means of meta-regressions and subgroup analyses. Furthermore, estimates derived from pooling together only those studies which carried out corrections for mismatching, despite representing a subset of all investigations retained totalling a lower sample size of patients, are more reliable and statistically robust, which represents a strength of our study, and has been confirmed by subsequent RCTs. Finally, we also included several studies awaiting for formal peer review, which could also represent a study limitation, even though meta-regression analysis showed no statistically significant differences between peer-reviewed articles and pre-prints. Hence, the peer reviewed published articles show a protective effect of tocilizumab in COVID-19 pneumonia.

It is important to mention that controls were treated with standard-of-care treatments, including hydroxychloroquine, azithromycin, antiviral therapy and heparin in most cases. In this meta-analysis, all studies (with the exception of three studies) included antivirals and corticosteroids in both the tocilizumab and standard-of-care group. Recent press release and preprint server publications showed a greater survival for corticosteroids over standard of care in ventilated cases over non-ventilated ill COVID-19 patients, but we were unable to accurately interrogate the data to evaluate this issue with respect to tocilizumab administration since it was often unclear in what setting tocilizumab was administered. Furthermore, the impact on antiviral therapy in limiting SARS-CoV2 replication in the face of steroid and tocilizumab therapy needs consideration as a potential factor that may contribute to the apparent benefit of tocilizumab. Although in some studies, certain disorders such as hypertension and chronic pulmonary disease were more prevalent among those treated with tocilizumab than controls, the overall rate of underlying co-morbidities was comparable between the two groups.

In conclusion, this systematic review and meta-analysis of case-control studies and unadjusted analysis in large numbers of cases failed to show a benefit of tocilizumab in a real-world setting type scenario. However, adjusted analysis in smaller numbers showed that tocilizumab may reduce death rates in severe COVID-19.

These preliminary findings including case control and pre-print server studies were subsequently confirmed by large RCTs and meta-analysis of these RCTs that showed incremental benefit with tocilizumab [64] [65] [66] . Therefore, our systematic literature review and meta-analysis strategy at the start of the pandemic with large numbers of cases point towards the robustness of such a strategy early in the face of the pandemic. Summarizing, early use of case control studies including non-peer reviewed data seem to provide valuable information in the face of a rapidly escalating pandemic. 

The Novel Coronavirus: A Bird's Eye View

Novel coronavirus: Where we are and what we know

COVID-19) epidemics, the newest and biggest global health threats: What lessons have we learned?

Coronavirus infections and immune responses

COVID-19: A clue from innate immunity

Cytokine release syndrome in severe COVID-19

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy

Tocilizumab for the treatment of adult-onset Still's disease. Expert Opin

The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody

Blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders

Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: A possible indication for deeper targeting IL-6

Effective treatment of severe COVID-19 patients with tocilizumab

Why tocilizumab could be an effective treatment for severe COVID-19?

Early Short Course Corticosteroids in Hospitalized Patients with COVID-19

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement

Quantifying heterogeneity in a meta-analysis

Measuring inconsistency in meta-analyses

Multivariable prediction model of intensive care unit transfer and death: A French prospective cohort study of COVID-19 patients

The association between treatment with heparin and survival in patients with Covid-19

Efficacy and safety of tocilizumab in severe COVID-19 patients: A single-centre retrospective cohort study

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study

The Covid Irccs San Matteo Pavia Task Force

Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in hospitalized patients

Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: A retrospective cohort study

COVID-19 Case Series at UnityPoint Health St. Lukes Hospital in Cedar Rapids, IA. medRxiv 2020

Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: A retrospective controlled cohort study

Patient trajectories and risk factors for severe outcomes among persons hospitalized for COVID-19 in the Maryland/DC region

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia

Tocilizumab in patients with severe COVID-19: A retrospective cohort study

Lack of Tocilizumab effect on mortality in COVID19 patients

Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients-An Observational Study

Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study

IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study

Tocilizumab and steroid treatment in patients with severe Covid-19 pneumonia

Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study

Comparative Survival Analysis of Immunomodulatory Therapy for COVID-19 'Cytokine Storm': A Retrospective Observational Cohort Study

First Consecutive 5000 Patients with Coronavirus Disease 2019 from Qatar: A Nation-wide Cohort Study

Broncho-alveolar inflammation in COVID-19 patients: A correlation with clinical out come

Use of High Flow Nasal Therapy to Treat Moderate to Severe Hypoxemic Respiratory Failure in COVID-19

ROX Index Predicts Intubation in Patients with COVID-19 Pneumonia and Moderate to Severe Hypoxemic Respiratory Failure Receiving High Flow Nasal Therapy

Prevalence and risk factors for mortality related to COVID-19 in a severely affected area of Madrid

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial

Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care

Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study

Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab-A Case-Controlled Study

Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: A cohort study

Interleukin-6 blockade for severe COVID-19. medRxiv 2020

Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration

HLH Across Speciality Collaboration, UK. COVID-19: Consider cytokine storm syndromes and immunosuppression

The COVID-19 Cytokine Storm; What We Know So Far. Front

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How? JAMA 2021

Informed Consent Statement: Not applicable.

All data relevant to the study are included in the article.

The authors declare no conflict of interest.